Therapeutic Area | MeSH |
---|---|
cardiovascular diseases | D002318 |
nutritional and metabolic diseases | D009750 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
CRESTOR | AstraZeneca | N-021366 RX | 2003-08-12 | 4 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ROSZET | Althera Pharmaceutical | N-213072 DISCN | 2021-03-23 | 4 products, RLD |
Brand Name | Status | Last Update |
---|---|---|
crestor | New Drug Application | 2024-07-31 |
ezallor sprinkle | New Drug Application | 2025-03-11 |
rosuvastatin | ANDA | 2025-09-25 |
rosuvastatin calcium | ANDA | 2025-10-01 |
rosuvastatin rosuvastatin calcium | ANDA | 2025-01-17 |
Expiration | Code | ||
---|---|---|---|
ROSUVASTATIN CALCIUM, CRESTOR, IPR | |||
2023-05-27 | ODE-118 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypercholesterolemia | D006937 | — | — | 3 | 2 | 23 | 7 | 10 | 45 |
Dyslipidemias | D050171 | — | — | 4 | 1 | 11 | 2 | 6 | 23 |
Atherosclerosis | D050197 | EFO_0003914 | I25.1 | 2 | 2 | 3 | 4 | — | 11 |
Hyperlipidemias | D006949 | EFO_0003774 | E78.5 | — | 3 | 2 | 3 | 2 | 10 |
Coronary artery disease | D003324 | — | I25.1 | 1 | 1 | 4 | 2 | 2 | 10 |
Coronary disease | D003327 | — | — | — | — | 3 | 2 | 3 | 8 |
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 2 | — | 2 | 4 | 8 |
Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | 2 | 1 | 2 | 5 |
Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 1 | 1 | 1 | 2 | 5 |
Hyperlipoproteinemia type ii | D006938 | EFO_0004911 | E78.00 | — | — | 4 | 1 | — | 5 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Heart failure | D006333 | EFO_0003144 | I50 | — | 1 | 3 | — | — | 4 |
Homozygous familial hypercholesterolemia | D000090542 | — | — | — | — | 2 | — | — | 2 |
Renal insufficiency | D051437 | — | N19 | 1 | — | 1 | — | — | 2 |
Stroke | D020521 | EFO_0000712 | I63.9 | — | — | 1 | — | 1 | 2 |
Hyperlipoproteinemia type iii | D006952 | — | — | — | — | 1 | — | — | 1 |
Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | 1 | — | — | 1 |
Recurrence | D012008 | — | — | — | — | 1 | — | — | 1 |
Cerebrovascular disorders | D002561 | EFO_0003763 | I60-I69 | — | — | 1 | — | — | 1 |
Cerebral infarction | D002544 | — | I63 | — | — | 1 | — | — | 1 |
Venous thrombosis | D020246 | — | I82.40 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Inflammation | D007249 | MP_0001845 | — | 1 | 2 | — | — | — | 3 |
Craniocerebral trauma | D006259 | — | S00 | 1 | 2 | — | — | — | 2 |
Amnesia | D000647 | EFO_1001454 | F44.0 | 1 | 2 | — | — | — | 2 |
Spatial orientation | D000072458 | — | — | 1 | 2 | — | — | — | 2 |
Proteinuria | D011507 | — | R80 | — | 2 | — | — | — | 2 |
Amyloid plaque | D058225 | — | — | — | 1 | — | — | — | 1 |
Depression | D003863 | — | F33.9 | — | 1 | — | — | — | 1 |
Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 11 | — | — | — | 1 | 12 |
Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 1 | — | — | — | — | 1 |
Arthritis | D001168 | EFO_0005856 | M05-M14 | 1 | — | — | — | — | 1 |
Neoplasms | D009369 | — | C80 | 1 | — | — | — | — | 1 |
Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | — | — | — | 1 |
Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Peripheral vascular diseases | D016491 | EFO_0003875 | I73.9 | — | — | — | — | 2 | 2 |
Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | — | — | 1 | 1 |
Peripheral arterial disease | D058729 | EFO_0004265 | — | — | — | — | — | 1 | 1 |
Observation | D019370 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Rosuvastatin |
INN | rosuvastatin |
Description | Rosuvastatin is a dihydroxy monocarboxylic acid that is (6E)-7-{4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl} hept-6-enoic acid carrying two hydroxy substituents at positions 3 and 5 (the 3R,5S-diastereomer). It has a role as an antilipemic drug, an anti-inflammatory agent, a CETP inhibitor, a cardioprotective agent, a xenobiotic and an environmental contaminant. It is a member of pyrimidines, a sulfonamide, a dihydroxy monocarboxylic acid, a statin (synthetic) and a member of monofluorobenzenes. It is functionally related to a hept-6-enoic acid. It is a conjugate acid of a rosuvastatin(1-). |
Classification | Small molecule |
Drug class | enzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O |
PDB | — |
CAS-ID | 287714-41-4 |
RxCUI | — |
ChEMBL ID | CHEMBL1496 |
ChEBI ID | 38545 |
PubChem CID | 446157 |
DrugBank | DB01098 |
UNII ID | 413KH5ZJ73 (ChemIDplus, GSRS) |